Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-06-26 EDT			Pre-market 08:37:17
901.3 ^USD	-0.37%		906	+0.53%

06-26	Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	CI
06-25	Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	MT

Eli Lilly and Company Appoints Martin Bott to Board of Directors

January 13, 2017 at 03:42 pm

InMed Pharmaceuticals Inc. announced that Martin Bott, VP of Corporate Finance and Investment Banking at Eli Lilly & Company, has been appointed to InMed Board of Directors effective immediately. Mr. Bott brings over 28 years of senior financial and executive leadership to InMed's Board of Directors.

Latest news about Eli Lilly and Company

Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	06-25	CI
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	06-25	MT
Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens	06-25	DJ
Eli Lilly Teams Up With OpenAI to Develop Antimicrobials for Drug-Resistant Bacteria	06-25	MT
Eli Lilly: collaboration agreement with OpenAI	06-25	CF
Eli Lilly Partners With OpenAI for Developing Antimicrobials to Treat Drug-Resistant Bacteria	06-25	MT
Out with AI, in with defensive stocks	06-25
Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China	06-25	DJ
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	06-25
Truist Adjusts Price Target on Eli Lilly & Co. to $1,000 From $892 After Model Update, Maintains Buy Rating	06-25	MT
Trending : Lilly Anti-Obesity Drug Tirzepatide Reduces Sleep Apnea Severity in Studies	06-24	DJ
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing	06-24	RE
Shares of ResMed, Inspire Medical Down After Eli Lilly Provides Sleep Apnea Study Update	06-24	DJ
Doctors must keep Ozempic prescriptions in check, Danish regulator says	06-24	RE
Eli Lilly Keeps Quarterly Dividend at $1.30 a Share, Payable Sept. 10 to Shareholders of Record on Aug. 15	06-24	MT
Eli Lilly and Company Declares Dividend for the Third Quarter of 2024, Payable on September 10, 2024	06-24	CI
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
Key week for monetary policy	06-24
What other health conditions are weight-loss drugs being tested for?	06-24	RE
Jefferies Adjusts Price Target on Eli Lilly to $1,015 From $994	06-24	MT
Eli Lilly Weight-loss Drug Found to Benefit Obese Adults With Obstructive Sleep Apnea	06-22	MT
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	06-21	RE
Eli Lilly and Company Announces Detailed Results from the Surmount-OSA Phase 3 Clinical Trials Evaluating Tirzepatide Injection	06-21	CI
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says	06-21	RE
Eli Lilly Sues More Wellness Centers, Medical Spas Over Unauthorized Tirzepatide Sales	06-21	MT

Chart Eli Lilly and Company

Duration

Period

More charts

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 12, 2024 at 02:47 pm

More Strategies

Ratings for Eli Lilly and Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

901.3 USD

Average target price

860.5 USD

Spread / Average Target

-4.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.76%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+17.66%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.64%	218B
AMGEN INC.	+8.61%	168B
PFIZER, INC.	-4.76%	155B

Other Pharmaceuticals